Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATNM logo ATNM
Upturn stock ratingUpturn stock rating
ATNM logo

Actinium Pharmaceuticals Inc (ATNM)

Upturn stock ratingUpturn stock rating
$1.44
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: ATNM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5

1 Year Target Price $5

Analysts Price Target For last 52 week
$5 Target price
52w Low $1.03
Current$1.44
52w High $8.64

Analysis of Past Performance

Type Stock
Historic Profit 15.85%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 44.92M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 5
Beta -0.3
52 Weeks Range 1.03 - 8.64
Updated Date 07/3/2025
52 Weeks Range 1.03 - 8.64
Updated Date 07/3/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.47

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -39.14%
Return on Equity (TTM) -130.87%

Valuation

Trailing PE -
Forward PE 6.84
Enterprise Value -19281876
Price to Sales(TTM) 652.71
Enterprise Value -19281876
Price to Sales(TTM) 652.71
Enterprise Value to Revenue 1726.07
Enterprise Value to EBITDA -3.62
Shares Outstanding 31195900
Shares Floating 31037728
Shares Outstanding 31195900
Shares Floating 31037728
Percent Insiders 1.79
Percent Institutions 29.96

ai summary icon Upturn AI SWOT

Actinium Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative targeted therapies for advanced cancers. Founded in 2011, it aims to deliver potent and selective treatments through its Antibody RadioConjugates (ARCs) platform.

business area logo Core Business Areas

  • Therapeutic Development: Actinium focuses on developing targeted radiotherapies that use antibodies to deliver radioisotopes directly to cancer cells, minimizing damage to healthy tissue.

leadership logo Leadership and Structure

The leadership team comprises experienced executives in the biopharmaceutical industry. The organizational structure includes research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Iomab-B: Iomab-B (Bexarotene Iodine I 131) is Actinium's most advanced product candidate, intended as a conditioning regimen prior to hematopoietic stem cell transplant (HSCT) in patients with relapsed or refractory acute myeloid leukemia (r/r AML). There is no direct market share data available as the product is under development. Competitors include conditioning regimens using chemotherapy. There are a few other companies which are developing similar drug products, but they are not yet FDA approved.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense research and development, stringent regulatory requirements, and high competition. Targeted therapies are a growing segment.

Positioning

Actinium is positioned as a specialist in targeted radiotherapies, particularly focusing on hematological malignancies. Their competitive advantage lies in their ARC platform.

Total Addressable Market (TAM)

The TAM for targeted cancer therapies is substantial and growing. Actinium is positioned to capture a segment of the market for conditioning regimens for stem cell transplantation, which is a large potential market. The total market value is estimated to be over $30 billion.

Upturn SWOT Analysis

Strengths

  • Proprietary ARC platform
  • Targeted therapy approach
  • Potential for improved efficacy and reduced toxicity compared to traditional therapies
  • Experienced management team

Weaknesses

  • Reliance on single product candidate (Iomab-B)
  • High R&D costs
  • Regulatory and clinical trial risks
  • Currently generating minimal revenue

Opportunities

  • Potential for label expansion of Iomab-B to other indications
  • Partnerships and collaborations
  • Advancements in radioisotope technology
  • Growing demand for targeted cancer therapies

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles
  • Reimbursement challenges

Competitors and Market Share

competitor logo Key Competitors

  • BPMC
  • CLVS
  • SNY

Competitive Landscape

Actinium's competitive advantage lies in its proprietary ARC platform. However, it faces competition from larger pharmaceutical companies with greater resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is largely tied to the progression of their clinical trials.

Future Projections: Future growth is heavily dependent on the successful clinical trials of Iomab-B and regulatory approvals. Analyst estimates will vary based on these factors.

Recent Initiatives: Recent initiatives include ongoing clinical trials of Iomab-B and expanding the pipeline.

Summary

Actinium Pharmaceuticals is a clinical-stage company with a promising platform for targeted radiotherapies. The company's success hinges on the clinical trial outcomes of Iomab-B. While their ARC platform holds significant potential, they face numerous risks associated with clinical development and regulatory approval. They must carefully manage their cash burn rate, especially as they are generating minimal revenues.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Actinium Pharmaceuticals Inc. website
  • SEC filings
  • Financial news sources
  • Industry reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investing in Actinium Pharmaceuticals Inc. involves significant risks, including the risk of loss.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Actinium Pharmaceuticals Inc

Exchange NYSE MKT
Headquaters New York, NY, United States
IPO Launch date 2012-12-27
Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 31
Full time employees 31

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.